{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-006881","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.458285+00:00","generated_at":"2026-05-17T01:01:59.254277+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria","bullets":["ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).","Net income $12.9M ($0.06) vs net loss $14.0M ($0.07 loss) prior year; non-GAAP net income $35.6M ($0.17).","FY 2025 ORLADEYO rev guidance raised to $590-600M; non-GAAP op expense lowered to $430-440M; on track for positive cash flow.","Sale of European ORLADEYO business closed; proceeds used to retire remaining $198.7M Pharmakon term debt; pro forma cash $294M.","Definitive agreement to acquire Astria Therapeutics (navenibart Phase 3 HAE); expected close Q1 2026; Ron Dullinger named CCO effective Jan 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-006881","json":"https://secwatch.observer/filing/0001171843-25-006881.json","markdown":"https://secwatch.observer/filing/0001171843-25-006881.md","text":"https://secwatch.observer/filing/0001171843-25-006881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/0001171843-25-006881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/f8k_110325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:01:59.254277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}